Aflibercept in the Diabetic Macular Edema Treatment
Authors:
J. Studnička
Authors place of work:
Oční klinika FN a LF UK, Hradec Králové
přednostka prof. MUDr. Naďa Jirásková, Ph. D., FEBO
Published in the journal:
Čes. a slov. Oftal., 71, 2015, No. 5, p. 243-246
Category:
Original Article
Summary
Diabetic retinopathy is together with the diabetic macular edema the most common cause of vision loss in the working population. It is also the most common diabetic microvascular abnormality. Aflibercept is approved for the diabetic macular edema treatment, it is a recombinant fusion protein, binding VEGF A, B, and P1GF. The efficacy and safety of the treatment comparing with the laser treatment were set by VIVID-DME and VISTA–DME studies. The T DRCR.net study protocol confirmed the efficacy of aflibercept, ranibizumab, and bevacizumab in the treatment of diabetic macular edema. The best results in the whole group were obtained if using aflibercept, especially in the group of patients with worse initial visual acuity. In all three studies, the safety of intraviteraly applied aflibercept was proven.
Key words:
diabetic macular edema, aflibercept, ranibizumab, bevacizumab
Zdroje
1. Clarke, M.: Diabetic retinopathy – reasons for screening. In: Dodson, PM., Diabetic retinopathy. Oxford: Oxford University Press; 2008: 11–5.
2. Diabetic Retinopathy Clinical Research Network, Wells, JA., Glassman, AR. et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med, 372; 2015, 13: 1193–203.
3. Hirai, FE., Knudtson, MD., Klein, BE. et al.: Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol, 145; 2008: 700–6.
4. Cheung, N., Wong, TJ.: Diabetic retinopathy and systemic complications. In: Duh, EJ. (Ed): Diabetic retinopathy. New Jersey: Humana Press; 2009: 465–85. o
5. Korobelnik JF., Do, DV., Schmidt-Erfurth, U. et al.: Intravitreal aflibercept for diabetic macular edema. Ophthalmology, 121; 2014, 11: 2247–54.
6. Massin, P., Bandello, F., Garweg, JG. et al.: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care, 33; 2010, 11: 2399–405.
7. Mitchell, P., Bandello, F., Schmidt-Erfurth, U. et al.: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 118; 2011, 4: 615–25.
8. Nguyen, QD., Brown, DM., Marcus, DM. et al.: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology, 119; 2012, 4: 789–801.
9. Sosna T., Švancarová, R., Netuková, M. et al.: Nové postupy v léčbě diabetické makulopatie. Kazuistiky v diabetologii, 10; 2012: 15–22.
10. Zander, E., Herfurth, S., Bohl, B. et al.: Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Brit J Ophthalmol, 84; 2000: 871–6.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2015 Číslo 5
Najčítanejšie v tomto čísle
- Eye Myiasis – a Case Report
- Surgical Treatment of Diplopia in Patients with Endocrine Orbitopathy
- Solar Maculopathy after Watching the Partial Solar Eclipse
- Treating Diabetic Macular Edema by a Micropulse Laser – First Findings